The estimated Net Worth of James Mond is at least $2.47 Million dollars as of 8 September 2020. James Mond owns over 4,000 units of Adma Biologics Inc stock worth over $1,237,372 and over the last 10 years he sold ADMA stock worth over $0. In addition, he makes $1,237,420 as Executive Vice President, Chief Scientific Officer und Chief Medical Officer at Adma Biologics Inc.
James has made over 8 trades of the Adma Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of ADMA stock worth $8,800 on 8 September 2020.
The largest trade he's ever made was buying 10,000 units of Adma Biologics Inc stock on 9 November 2017 worth over $21,500. On average, James trades about 1,656 units every 115 days since 2014. As of 8 September 2020 he still owns at least 73,174 units of Adma Biologics Inc stock.
You can see the complete history of James Mond stock trades at the bottom of the page.
Dr. James Mond M.D., Ph.D. serves as Executive Vice President, Chief Scientific Officer, Chief Medical Officer of the Company. Dr. Mond joined the Company as Executive Vice President, Chief Scientific Officer and Chief Medical Officer in July 2012. Dr. Mond was most recently Chief Scientific Officer and Executive Vice President at Biosynexus, where he was responsible for the preclinical and clinical development of three drug candidates from December 1999 through June 2011. Biosynexus engaged in immunological and non-immunologic approaches to treat and prevent staphylococcus infections. Dr. Mond also functioned as its Chief Medical Officer and had involvement with the Food and Drug Administration in designing clinical studies. While at Biosynexus, Dr. Mond served as Chief Medical Officer for a Phase III clinical trial that was run in 93 neonatal intensive care units in Europe and North America. Prior to that time, he was professor of Medicine, Rheumatology and Immunology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, actively practicing internal medicine, rheumatology and teaching medical students. Dr. Mond’s laboratory invented a vaccine technology that was licensed to GlaxoSmithKline and is currently the basis of a number of pediatric vaccines that are commercialized globally. Dr. Mond also led the laboratory of Immunology at the Uniformed Services University of the Health Sciences and authored 168 papers published in peer reviewed scientific journals and 20 invited articles and book chapters. He has over 20 issued patents in the area of vaccines. Dr. Mond received his M.D and Ph.D. from the New York University Medical School.
As the Executive Vice President, Chief Scientific Officer und Chief Medical Officer of Adma Biologics Inc, the total compensation of James Mond at Adma Biologics Inc is $1,237,420. There are 1 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of $1,702,020.
James Mond is 73, he's been the Executive Vice President, Chief Scientific Officer und Chief Medical Officer of Adma Biologics Inc since 2019. There are 1 older and 9 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
James's mailing address filed with the SEC is 465 New Jersey 17 S, Ramsey, NJ 07446, United States.
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... und Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Inc executives and other stock owners filed with the SEC include: